ArticleDiscover nano2026
Response0 surface guided design of lipid-polymer hybrid nanoparticles for dual delivery of rosuvastatin and ezetimibe.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fixed-dose formulations of rosuvastatin and ezetimibe loaded lipid-polymer hybrid nanoparticles were developed, employing a combination of polymer and lipid components designed to achieve a potential core-shell-like structure through nanoprecipitation method. For building structure, poly-(DL)-lactic-co-glycolic acid, acid-or ester-terminated, and soy phosphatidylcholine combined either with 1,2-dioleoyl-3-trimethylammonium-propane chloride or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine as lipids were used along with α-hydro-ω-hydroxypoly(oxyethylene)poly(oxypropylene)poly(oxyethylene) block copolymer and polyoxyethylene (20) sorbitan monooleate as stabilizers. The effects of independent variables (lipid quantity and type, polymer type and total drugs quantity) on the response variables (particle size, polydispersity index, zeta potential, total drug loading and rosuvastatin to ezetimibe ratio) were evaluated using response surface methodology by Design-Expert
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.